[Summary]
Shimadzu Corporation (7701) is one of Japan's leading precision equipment manufacturers, focusing on analytical and measuring instruments.
What investors should look for is that the company is not just an equipment manufacturer, but is evolving into a recurring company that continues to generate revenue from maintenance, maintenance, software, and consumables even after the equipment is sold.
In the fiscal year ending March 2026, sales and profits increased with sales of 560.7 billion yen, operating income of 73.7 billion yen, and net income of 60.5 billion yen.
On the other hand, the forecast for the fiscal year ending March 2027 is that sales and operating income will increase, but ordinary income and net income are expected to decrease.
Therefore, the stock price in 2026-2027 will be more than a "skyrocketing theme stock".
Can you pick up stable growth stocks at the right time?
becomes the focus.
What kind of company is Shimadzu?
Shimadzu Corporation is a precision equipment manufacturer that produces analytical and measuring equipment, medical equipment, industrial equipment, and aviation equipment.
It is also known as the company where Koichi Tanaka, winner of the Nobel Prize in Chemistry, works, but what is important from an investor's perspective is that it is an equipment company that supports a wide range of industries, including research, medicine, the environment, food, pharmaceuticals, and semiconductors.
The main businesses are as follows.
| Business | Main products and applications | Characteristics from an investor's perspective |
|---|---|---|
| Measuring equipment | Liquid chromatographs, mass spectrometers, etc. | Pillars of sales and profits. Used in pharmaceuticals, food, environment, and semiconductor development |
| Medical equipment | X-ray imaging systems, etc. | Stable demand for hospitals and medical institutions |
| Industrial equipment | Turbomolecular pumps, etc. | Related to demand for semiconductor manufacturing equipment |
| Aviation equipment | Aircraft equipment | Linked with defense and aviation demand |
Looking at sales for the fiscal year ending March 2026, measuring equipment is 364.9 billion yen, making it the mainstay of company-wide sales.
The essence of the business model is recurring
Shimadzu's strength lies in the fact that it does not end with selling equipment.
Analyzers are used continuously in research and quality control sites such as pharmaceutical companies, universities, hospitals, food manufacturers, and semiconductor-related companies.
Therefore, even after the equipment is installed, it is easy to generate the following profits.
- Maintenance/maintenance contract *Remote maintenance
- Software license
- Consumables such as reagents, media, columns, etc.
- Maintenance parts sales
Shimadzu's medium-term business plan also calls for expanding service contracts using DX, IoT, remote monitoring, and remote maintenance, software licensing using AI, and expanding recurring businesses such as reagents, culture media, and columns.
In other words, Shimadzu is not just a precision equipment manufacturer;
A company that charges recurring fees for analysis infrastructure in research, medical, and industrial settings
should be viewed as such.
Key points of financial results for the fiscal year ending March 2026
The financial results for the fiscal year ending March 2026, announced on May 12, 2026, were solid.
| Item | Fiscal year ending March 2026 | Comparison with previous period |
|---|---|---|
| Sales | 560.7 billion yen | +4.0% |
| Operating income | 73.7 billion yen | +2.8% |
| Ordinary profit | 82.8 billion yen | +14.9% |
| Net income attributable to owners of parent company | 60.5 billion yen | +12.5% |
| Equity ratio | 76.6% | +2.5pt |
| Dividend per share | 69 yen | +3 yen |
Sales increased and operating income remained at record high levels.
In particular, ordinary income increased significantly due in part to foreign exchange gains in non-operating income.
Financially, the company has a high equity ratio of 76.6%, making it a typical blue-chip stock with high financials and stable growth.
China's weakness is an issue by region
Looking at sales by region for the fiscal year ending March 2026, sales increased in Japan, Europe, and other Asian countries, but only slightly increased in China.
| Region | Sales for the fiscal year ending March 2026 | Compared to the previous year |
|---|---|---|
| Japan | 242.6 billion yen | +3.4% |
| Americas | 81.9 billion yen | +4.2% |
| Europe | 54.8 billion yen | +10.6% |
| China | 91.7 billion yen | +0.4% |
| Other Asia | 71.5 billion yen | +10.0% |
The slow recovery in the Chinese market is likely to weigh on the revaluation of stock prices.
Since Shimadzu is a global company, it will receive a tailwind if China's pharmaceutical, university, and private R&D investment recovers in earnest.
Conversely, if Chinese demand continues to stagnate, it will be difficult for stock prices to command high valuations.
Why the forecast for the fiscal year ending March 2027 suppresses the top price of stock prices
The company's forecast for the fiscal year ending March 2027 is that sales and operating income will increase, but ordinary income and net income are expected to decrease.
| Item | Forecast for the fiscal year ending March 2027 | Compared to the previous year |
|---|---|---|
| Sales | 575 billion yen | +2.5% |
| Operating income | 76 billion yen | +3.1% |
| Ordinary profit | 75 billion yen | -9.4% |
| Net income attributable to owners of parent company | 55 billion yen | -9.1% |
| Dividend per share | 70 yen | +1 yen |
Although operating income is expected to increase, net income is expected to decrease, so short-term investors will likely find the company unsatisfactory.
Additionally, the company is making investments for future growth, including strengthening its global manufacturing system, promoting DX, strengthening its development capabilities, and expanding recurring sales.
This is positive in the long term, but in the short term it tends to be a factor that suppresses profit margin growth.
Stock price trend: more of a dip than a flashy spike
As of May 2026, Shimadzu shares are hovering around the 3,600 to 3,800 yen range, which is not at the high range of the past year, but rather at a level that is slightly adjusted.
In the 52-week range, price movements have been confirmed from the 3,200 yen level to the 4,500 yen level, and rather than chasing the high price recently, the stock seems to be exploring the downside while digesting the business outlook.
As an investment strategy, rather than aiming for a short-term spike, the following idea of buying in installments is more realistic.
| Guide to stock price levels | How to view |
|---|---|
| 3,200 to 3,400 yen range | Potential candidate for long-term investors |
| Around 3,600 yen | Candidate to wait and buy in installments |
| Over 4,000 yen | Level at which we want to confirm recovery in China and re-acceleration of profits |
Of course, this is not a recommendation to buy or sell.
What is important is that Shimadzu is not a short-term theme stock like Lasertec or Fujikura, but a stock whose performance and recurring ratio are checked over several years.
5 checkpoints investors should look at
The following five points are important when looking at Shimadzu's future.
| Check items | Reasons to watch |
|---|---|
| Growth rate of analytical and measuring instruments | Confirming the strength of our main business |
| Expanding recurring sales | Confirming progress in stabilizing earnings |
| Recovery of sales in China | Catalyst for revaluation of stock prices |
| Operating profit margin | Can profitability be maintained while making growth investments |
| Next medium-term management plan | Confirmation of growth scenario from 2026 to 2028 |
Particularly important is the progress of China's recovery and recurrence.
If the ratio of maintenance, consumables, and software increases in addition to equipment sales, it will be easier for the market to evaluate Shimadzu as a stable and highly profitable company.
Stock price scenario for 2026-2027
Bullish scenario
In a bullish scenario, the following factors come together:
- Chinese market recovers
- Analytical and measuring instruments continue to grow in Europe, America and Asia
- Increased recurring sales *Operating profit margin improved
- Growth investment will start contributing to profits after 2027
In this case, the stock price will recover to the 4,000 yen level, and it will be easier to become aware of the past high range again.
Neutral scenario
In the neutral scenario, sales will increase, but profit margin improvement will be limited, and China's recovery will remain sluggish.
In this case, the stock price will likely remain in the range of around 3,400 to 4,000 yen, supported by dividends and a sense of financial security.
Bearish scenario
In a bearish scenario, we are aware of the following risks:
- Prolonged stagnation in Chinese demand
- Deterioration of exchange rate assumptions
- Increase in growth investment costs
- Decrease in operating profit margin
- Decrease in valuation of the precision equipment sector as a whole
In this case, there is a possibility that the price will reconfirm the downside of the 3,200 yen level.
Conclusion: Shimadzu is a stable growth stock suitable for long-term ownership
Shimadzu is not a stock aiming for a rapid rise in the short term.
However, it is an analytical infrastructure company that supports a wide range of industries, including medical, pharmaceutical, environmental, food, semiconductor, and aviation, and has a strong long-term business foundation.
In 2026-2027, due to the sluggish net profit outlook and the wait for a recovery in the Chinese market, stock prices are likely to be in a phase of adjustment and firming up medium- to long-term evaluations, rather than a sudden jump.
What is realistic for investors is
A strategy to pick up weak points by dividing while checking the strength of the business
It is.
What we should be watching is not short-term price movements, but the progress of recurring business and the recovery of the Chinese market.
Reference materials
- Shimadzu Corporation Financial Results for the Year Ending March 2026
- Shimadzu Corporation Mid-term Management Plan
- Matsui Securities Shimadzu Corporation (7701) stock price information